Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Problematic Use and Addiction in Primary Care

NCT06580756 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-09
Last updated
2024-12-09

Condition(s) studied

Addiction DisordersPrimary Care

Investigational drug(s) / intervention(s)

Short training program

Short training program: Training in the early identification of addictive disorders in primary care

Study summary

The morbi-mortality and social cost of addictive disorders led the French authorities to set up a government plan in 2018 to combat drugs and addictive behavior (Interministerial mission to combat drugs and addictive behaviour - (MILDECA)). In particular, it encourages early detection, which is the first stage in a validated global approach to the management of addictive disorders. Improving early identification of addictive disorders in primary care would reduce morbidity and mortality and improve quality of life for patients with addictive disorders. The identification of use disorders should be systematic in primary care and was the subject of a recommendation in 2015. Numerous tests are cited in these recommendations, but few have actually been validated in primary care, and none has been shown to be feasible. For example, only 23% of GPs claim to systematically identify alcohol consumption.

Other primary care professionals (physiotherapists, nurses, midwives, dentists, pharmacists) also have a role to play in identifying addictive disorders. The evolution of their respective professions (delegation of tasks, creation of the profession of advanced practice nurse, medical assistants) and the recent reorganization of the practice framework, both in terms of practice structures and professional community organizations, involve them in a global multidisciplinary collaboration on patient care, particularly in the early identification of addictive disorders.

The hypothesis is that the difficulties in implementing tests to identify addictive disorders in primary care are linked to the lack of specific consideration of the needs of primary care patients and caregivers.

The overall aim of the study is to improve the early detection of addictive disorders through brief training for primary care healthcare professionals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * be a primary care professional (physiotherapists, nurses, midwives, dentists, pharmacists, General practitioner) * in ambulatory practice. Recruitment will be carried out with the help of territorial professional health communities, to include practitioners practicing in conditions representative of the diversity of primary care practice. GPs agreeing to take part will be divided into a control group and an intervention group, by drawing lots. Exclusion Criteria: * Refusal to participate. * The same participant may not be included in more than one stage.

Primary outcome measure(s)

  • Number of patients who received information about the addictive disorders from the primary care professional — 24 months
    The main aim of the study was to measure the effect of brief training in the identification of addictive disorders on the rate of patients who actually received the information from the primary care professional.
  • number of patients identified with an addictive disorder from the primary care professional — 24 months
    The main aim of the study was to measure the effect of brief training in the identification of addictive disorders on the rate of patients who actually received the information from the primary care professional.

Trial sites (3)

FacilityCityRegionStatus
CPTS Lanmeur Lanmeur France
CPTS Sud Lochois Ligueil France
CPTS du Vendomois Vendôme France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06580756 on ClinicalTrials.gov ↗ ← All trials in France